107747-03-5

Upstream product

• 83057-00-5 (S)-3-benzyl-2-oxo-imidazolidine-1,5-dicarboxylic acid 1-benzyl ester 5-t-butyl ester 

Downstream Products

• 1037222-31-3 (4S)-1-benzyl-[(2S,3R)4-(3-dimethylaminophenyl)methylamino-3-hydroxy-1-phenylbutan-2-yl]-2-oxoimidazolidine-4-carboxamide 
• 1037222-49-3 (4S)-1-benzyl-N-[(2S,3R)-3-hydroxy-1-phenyl-4-[(3-trifluoromethylphenyl)methylamino]butan-2-yl]-2-oxoimidazolidine-4-carboxamide 
• 1037222-51-7 (3S)-1-benzyl-N-((2S,3R)-3-hydroxy-1-phenyl4-[(3-trifluoromethoxyphenyl)methylamino]butan-2-yl)-2-oxoimidazolidine4-carboxamide 
• 1037222-54-0 (S)-1-benzyl-N-[(2S,3S)-1-(3,5-difluorophenyl)-4-(3-dimethylaminophenyl)methylamino-3-hydroxybutan-2-yl]-2-oxoimidazolidine-4-carboxamide 

Relevant academic research and scientific papers

BETA-SECRETASE INHIBITING COMPOUNDS

Disclosed are compounds represented by Formula (I) as defined in the specification, or pharmaceutically acceptable salts or isomers thereof, and a pharmaceutical composition for inhibiting beta-secretase activity comprising a therapeutically effective amount of the same.

Synthesis, SAR, and X-ray structure of human BACE-1 inhibitors with cyclic urea derivatives

We describe synthesis and evaluation of a series of cyclic urea derivatives with hydroxylethylamine isostere. Modification of P3, P1, and P2′ and combination of SAR display a >100-fold increase in potency with good cellular activity (IC50 = 0.1